Nuvation Bio Q3 revenue rises on IBTROZI sales
NUVB•NUVB•NUVB•NUVB•Nuvation Bio's Q3 revenue rose to $45 million, while its net loss narrowed to $41.9 million from $55.8 million a year earlier. IBTROZI net product revenue increased 18% quarter over quarter.
Nuvation Bio reported Q3 revenue of $45 million, up from a year earlier, and a net loss of $41.9 million compared with $55.8 million last year. IBTROZI net product revenue rose 18% quarter over quarter, driven by continued adoption and treatment durability.
The FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma. Nuvation Bio is advancing Phase 2 and pivotal Phase 3 studies and expanding its SIGMA Phase 3 study to additional European countries.
The company plans further updates on its drug-drug conjugate platform by year-end 2026. Higher collaboration and license revenue reflected increased product supply revenue, a sales milestone and greater royalty income.
